Severe Aplastic Anemia Clinical Trials

84 clinical trials for Severe Aplastic Anemia across international registries, including 19 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome — RECRUITING · PHASE1
• Natural History of Acquired and Inherited Bone Marrow Failure Syndromes — RECRUITING
• A Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAA — RECRUITING
• A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) — RECRUITING
• Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells — RECRUITING · PHASE2
• Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis — RECRUITING · PHASE2
• TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children — RECRUITING · PHASE2
• Phase I Clinical Study of Haplo-HSCT Combined With Hypoxic 3D-Cultured Umbilical Cord MSC for the Treatment of SAA — RECRUITING · PHASE1
• MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure. — RECRUITING · PHASE2
• Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia — RECRUITING · PHASE2
• Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA) — RECRUITING · PHASE2
• Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia — RECRUITING · PHASE2
• Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders — RECRUITING · PHASE2
• AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion — RECRUITING · PHASE2
• CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia — RECRUITING · PHASE1
• Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia — RECRUITING · PHASE2
• Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia — RECRUITING · PHASE2
• Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness — RECRUITING · PHASE2
• RACE 2: a Long Term Follow-up of Patients Participating in the RACE Trial — RECRUITING
• A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) — ACTIVE_NOT_RECRUITING · PHASE3
• A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes — NOT_YET_RECRUITING · PHASE1
• JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure — ACTIVE_NOT_RECRUITING · PHASE1
• REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy — TERMINATED · PHASE1
• Peripheral Blood Versus Bone Marrow Plus Peripheral Blood Grafts for Haploidentical Transplantation in Severe Aplastic Anemia — NOT_YET_RECRUITING · NA
• CsA+EPAG/HPAG+Romiplostim N01 in the Treatment of Newly-diagnosed SAA/TD-NSAA — WITHDRAWN · PHASE2
• CsA+EPAG/HPAG+Romiplostim N01 in Newly-diagnosed SAA/TD-NSAA — NOT_YET_RECRUITING · PHASE2
• hATG+CsA vs hATG+CsA+Eltrombopag for SAA — COMPLETED · PHASE3
• Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant — ACTIVE_NOT_RECRUITING · PHASE1
• Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia — ACTIVE_NOT_RECRUITING · PHASE1
• Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502) — COMPLETED · PHASE2
• Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy — ACTIVE_NOT_RECRUITING · PHASE2
• Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia — COMPLETED · PHASE2
• Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia — NOT_YET_RECRUITING · PHASE1
• Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion — ACTIVE_NOT_RECRUITING · NA
• CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation — ACTIVE_NOT_RECRUITING · PHASE1
• Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer — TERMINATED · PHASE2
• Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia — COMPLETED · NA
• Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia — COMPLETED · PHASE3
• A Phase 1/2 Study of REGN7257 (Anti-Interleukin 2 Receptor Subunit Gamma [IL2RG] Monoclonal Antibody) in Patients with Severe Aplastic Anemia that is Refractory to or Relapsed on Immunosuppressive Therapy — OTHER · PHASE2
• Cyclophosphamide Added to Standard Immunosuppressive Therapy With Herombopag as Front-line Therapy in Patients With Severe Aplastic Anemia — ACTIVE_NOT_RECRUITING · PHASE2
• Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors — OTHER · PHASE1
• Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia — COMPLETED · PHASE2
• The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA — OTHER · PHASE4
• Conditioning Regimen Containing Low Dose ATG for The Treatment of Acquired SAA Receiving sUCBT — OTHER
• Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy — WITHDRAWN · PHASE2
• Extended Dosing With Eltrombopag for Severe Aplastic Anemia — COMPLETED · PHASE2
• The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia — COMPLETED · PHASE4
• Retrospective Study of Patients With Severe Aplastic Anemia Who Relapsed After Immunosuppressive Therapy — COMPLETED
• Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia — COMPLETED · PHASE2
• Avatrombopag Combined With IST as First-line Treatment for SAA — OTHER · PHASE2

Refine this search